MedTrace Logo

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

NCT01641510 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2019-02-11

No results posted yet for this study

Summary

The investigators hypothesize that reduced loading dose of prasugrel followed by reduced maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism undergoing percutaneous coronary intervention might exhibit lower platelet reactivity 24 hours and 30 days later which is associated with major adverse cardiovascular events.

Conditions

  • Acute Coronary Syndromes

Interventions

DRUG

Prasugrel

Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg

DRUG

Clopidogrel

Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Principal Investigators

  • Moo Hyun Kim, MD · Director, Regional Clinical Trial Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-10-31
Completion
2019-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01641510 on ClinicalTrials.gov